Contrast-enhanced ultrasound reveals perfusion differences between benign lipoma and semi-malignant atypical lipomatous tumors: A prospective clinical study
CONCLUSION: CEUS may enhance the differential diagnosis of benign lipomas and ALTs, with ALTs showing higher levels of perfusion. If larger prospective studies confirm these findings, CEUS could enhance diagnostic accuracy, guide surgical planning, and potentially reduce unnecessary treatments for patients presenting with ambiguous lipomatous tumors like lipoma or ALT. Abstract German Ziel: Die Unterscheidung zwischen gutartigen und bösartigen Weichteiltumoren gestaltet sich oftmals herausfordernd. Insbesondere benigne Lipome lassen sich nur schwer von semimalignen atypischen lipomatösen Tumoren (ALT) abgrenzen, welche i...
Source: Ultraschall in der Medizin - October 11, 2023 Category: Radiology Authors: Paul Mick Antonia Seeberger Tobias Renkawitz Burkhard Lehner Mustafa Hariri Christian Fischer Julian Doll Source Type: research
Contrast-enhanced ultrasound reveals perfusion differences between benign lipoma and semi-malignant atypical lipomatous tumors: A prospective clinical study
CONCLUSION: CEUS may enhance the differential diagnosis of benign lipomas and ALTs, with ALTs showing higher levels of perfusion. If larger prospective studies confirm these findings, CEUS could enhance diagnostic accuracy, guide surgical planning, and potentially reduce unnecessary treatments for patients presenting with ambiguous lipomatous tumors like lipoma or ALT. Abstract German Ziel: Die Unterscheidung zwischen gutartigen und bösartigen Weichteiltumoren gestaltet sich oftmals herausfordernd. Insbesondere benigne Lipome lassen sich nur schwer von semimalignen atypischen lipomatösen Tumoren (ALT) abgrenzen, welche i...
Source: Ultraschall in der Medizin - October 11, 2023 Category: Radiology Authors: Paul Mick Antonia Seeberger Tobias Renkawitz Burkhard Lehner Mustafa Hariri Christian Fischer Julian Doll Source Type: research
Case Report: Primary low-grade dedifferentiated liposarcoma of the urinary bladder with molecular confirmation
Liposarcomas originating in the urinary bladder are extremely rare. Only six cases of bladder liposarcoma have been reported, and all have been described as myxoid liposarcomas. Notably, none of the patients underwent molecular testing. Here, we report a dedifferentiated liposarcoma (DDL) that occurred in the urinary bladder, primarily in a 69-year-old Chinese woman, with infrequent low-grade dedifferentiation. Computed tomography (CT) revealed an ill-defined solid mass in the anterior bladder wall. The patient underwent a partial bladder resection. Histologically, the tumor cells with mild-to-moderate nuclear atypia were ...
Source: Frontiers in Oncology - October 10, 2023 Category: Cancer & Oncology Source Type: research
Predictive factors assessment of pathological response to neoadjuvant radiotherapy of soft tissue sarcomas
CONCLUSIONS: Neoadjuvant radiotherapy is well-tolerated. No clinical, radiological or pathological predictive factors was identified for radiotherapy tumour response.PMID:37813717 | DOI:10.1016/j.canrad.2023.02.003 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - October 9, 2023 Category: Cancer & Oncology Authors: N Hanslik C Bourgier S Thezenas S Carr ère N Firmin O Riou D Azria C Llacer-Moscardo Source Type: research
Predictive factors assessment of pathological response to neoadjuvant radiotherapy of soft tissue sarcomas
CONCLUSIONS: Neoadjuvant radiotherapy is well-tolerated. No clinical, radiological or pathological predictive factors was identified for radiotherapy tumour response.PMID:37813717 | DOI:10.1016/j.canrad.2023.02.003 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - October 9, 2023 Category: Cancer & Oncology Authors: N Hanslik C Bourgier S Thezenas S Carr ère N Firmin O Riou D Azria C Llacer-Moscardo Source Type: research
Predictive factors assessment of pathological response to neoadjuvant radiotherapy of soft tissue sarcomas
CONCLUSIONS: Neoadjuvant radiotherapy is well-tolerated. No clinical, radiological or pathological predictive factors was identified for radiotherapy tumour response.PMID:37813717 | DOI:10.1016/j.canrad.2023.02.003 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - October 9, 2023 Category: Cancer & Oncology Authors: N Hanslik C Bourgier S Thezenas S Carr ère N Firmin O Riou D Azria C Llacer-Moscardo Source Type: research
Predictive factors assessment of pathological response to neoadjuvant radiotherapy of soft tissue sarcomas
CONCLUSIONS: Neoadjuvant radiotherapy is well-tolerated. No clinical, radiological or pathological predictive factors was identified for radiotherapy tumour response.PMID:37813717 | DOI:10.1016/j.canrad.2023.02.003 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - October 9, 2023 Category: Cancer & Oncology Authors: N Hanslik C Bourgier S Thezenas S Carr ère N Firmin O Riou D Azria C Llacer-Moscardo Source Type: research
One rare case of chronic kidney disease accompanied by a huge renal liposarcoma in the right kidney
Asian J Surg. 2023 Oct 2:S1015-9584(23)01480-X. doi: 10.1016/j.asjsur.2023.09.064. Online ahead of print.NO ABSTRACTPMID:37793943 | DOI:10.1016/j.asjsur.2023.09.064 (Source: Asian Journal of Surgery)
Source: Asian Journal of Surgery - October 4, 2023 Category: Surgery Authors: Hong-Jiang Fu Zhen-Shan Li Jun Wan Jin-Yang Ma Source Type: research
High dose, dual-release polymeric films for extended surgical bed paclitaxel delivery
We describe an implantable, biodegradable poly(1,2-glycerol carbonate) and poly(caprolactone) film with entrapped and covalently-bound paclitaxel enabling safe, controlled, and extended local delivery of paclitaxel achieving concentrations 10,000× tissue levels compared to systemic administration. Films containing entrapped and covalently-bound paclitaxel implanted in the tumor bed, immediately after resection of human cell line-derived chondrosarcoma and patient-derived xenograft liposarcoma and leiomyosarcoma in mice, improve median 90- or 200-day recurrence-free and overall survival compared to control mice. Furthermor...
Source: Cancer Control - September 30, 2023 Category: Cancer & Oncology Authors: David A Mahvi Jenny Korunes-Miller Catalina Bordeianu Ngoc-Quynh Chu Abraham D Geller Robbie Sabatelle Samantha Berry Yin P Hung Yolonda L Colson Mark W Grinstaff Chandrajit P Raut Source Type: research
Distribution and Rate of Myxoid Liposarcoma Spine Metastases: Impact on Surveillance Imaging
CONCLUSION: Spine metastases occurred in nearly one-quarter of patients with myxoid LPS and represented an advanced disease state, as they primarily presented in the setting of synchronous, non-spine metastases, and were associated with worse overall survival. Routine surveillance with spine MRI in patients with localized disease likely provides no benefit but may be considered in those with known metastatic disease.PMID:37773566 | DOI:10.1245/s10434-023-14309-2 (Source: Ann Oncol)
Source: Ann Oncol - September 29, 2023 Category: Cancer & Oncology Authors: Benjamin M Vierra Lily V Saadat Jason L Hornick Jyothi P Jagannathan Marco L Ferrone Andrew J Wagner Jiping Wang Elizabeth H Baldini Chandrajit Raut Mark Fairweather Source Type: research
Distribution and Rate of Myxoid Liposarcoma Spine Metastases: Impact on Surveillance Imaging
CONCLUSION: Spine metastases occurred in nearly one-quarter of patients with myxoid LPS and represented an advanced disease state, as they primarily presented in the setting of synchronous, non-spine metastases, and were associated with worse overall survival. Routine surveillance with spine MRI in patients with localized disease likely provides no benefit but may be considered in those with known metastatic disease.PMID:37773566 | DOI:10.1245/s10434-023-14309-2 (Source: Ann Oncol)
Source: Ann Oncol - September 29, 2023 Category: Cancer & Oncology Authors: Benjamin M Vierra Lily V Saadat Jason L Hornick Jyothi P Jagannathan Marco L Ferrone Andrew J Wagner Jiping Wang Elizabeth H Baldini Chandrajit Raut Mark Fairweather Source Type: research
Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial
This study is registered with ClinicalTrials.gov, NCT03890068.FINDINGS: At the data cut-off date (August 8, 2022), 49 patients were enrolled, including 17 with liposarcoma (35%) and 15 with leiomyosarcoma (31%). After a median follow-up of 17.1 months (IQR 9.0-27.2), the median PFS from the beginning of maintenance treatment was 9.1 months (95% CI 5.7-12.5), and the median OS was not reached, and the 1-year OS rate for anlotinib maintenance treatment was 98.0%. The best ORR and DCR were 16% (8/49, 95% CI 7-30) and 94% (46/49, 95% CI 83-99), respectively. Most of the treatment-related adverse events were grade 1-2. Of the g...
Source: Cancer Control - September 28, 2023 Category: Cancer & Oncology Authors: Bushu Xu Qiuzhong Pan Hua Pan Haomiao Li Xianan Li Jing Chen Danmei Pang Baoqing Zhang Desheng Weng Ruiqing Peng Meiyu Fang Xing Zhang Source Type: research
Discoidin Domain Receptor Tyrosine Kinase 1 (DDR1) Is a Novel Therapeutic Target in Liposarcoma: A Tissue Microarray Study
CONCLUSION: DDR1 is aberrantly expressed in liposarcoma, and it contributes to several markers of oncogenesis in these tumors.CLINICAL RELEVANCE: This work supports DDR1 as a promising therapeutic target in liposarcoma.PMID:37768856 | DOI:10.1097/CORR.0000000000002865 (Source: Clinical Orthopaedics and Related Research)
Source: Clinical Orthopaedics and Related Research - September 28, 2023 Category: Orthopaedics Authors: Dylan C Dean Wenlong Feng Robert L Walker Pichaya Thanindratarn H Thomas Temple Jonathan C Trent Andrew E Rosenberg Francis J Hornicek Zhenfeng Duan Source Type: research
Discoidin Domain Receptor Tyrosine Kinase 1 (DDR1) Is a Novel Therapeutic Target in Liposarcoma: A Tissue Microarray Study
CONCLUSION: DDR1 is aberrantly expressed in liposarcoma, and it contributes to several markers of oncogenesis in these tumors.CLINICAL RELEVANCE: This work supports DDR1 as a promising therapeutic target in liposarcoma.PMID:37768856 | DOI:10.1097/CORR.0000000000002865 (Source: Clinical Orthopaedics and Related Research)
Source: Clinical Orthopaedics and Related Research - September 28, 2023 Category: Orthopaedics Authors: Dylan C Dean Wenlong Feng Robert L Walker Pichaya Thanindratarn H Thomas Temple Jonathan C Trent Andrew E Rosenberg Francis J Hornicek Zhenfeng Duan Source Type: research
Clinical characteristics of sarcoma patients: a population-based data analysis from a German clinical cancer registry
CONCLUSIONS: Histological grade, tumor size, nodal and distant metastasis, tumor localization and histological subtype were determined as prognostic factors in terms of survival.PMID:37750956 | DOI:10.1007/s00432-023-05350-5 (Source: Cancer Control)
Source: Cancer Control - September 26, 2023 Category: Cancer & Oncology Authors: J örg Andreas Müller Karl-Stefan Delank Kevin Laudner Ian Wittenberg Alexander Zeh Dirk Vordermark Daniel Medenwald Source Type: research
